Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Feb

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

David A. Hyman, MD, JD, on Inclusive Shared Savings

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma

Oncolytic Virus Triggers Immune System Against Glioblastoma Cells

Adjuvant Durvalumab in Resected Early-Stage NSCLC

FDA Approves Labeling Changes to Menopausal Hormone Therapy Products

Young-Onset Pancreatic Cancer Can Alcohol Consumption Raise Risk